Scaffold Hopping and Optimization of Small Molecule Soluble Adenyl Cyclase Inhibitors Led by Free Energy Perturbation.


Journal

Journal of chemical information and modeling
ISSN: 1549-960X
Titre abrégé: J Chem Inf Model
Pays: United States
ID NLM: 101230060

Informations de publication

Date de publication:
08 05 2023
Historique:
medline: 9 5 2023
pubmed: 16 4 2023
entrez: 15 4 2023
Statut: ppublish

Résumé

Free energy perturbation is a computational technique that can be used to predict how small changes to an inhibitor structure will affect the binding free energy to its target. In this paper, we describe the utility of free energy perturbation with FEP+ in the hit-to-lead stage of a drug discovery project targeting soluble adenyl cyclase. The project was structurally enabled by X-ray crystallography throughout. We employed free energy perturbation to first scaffold hop to a preferable chemotype and then optimize the binding affinity to sub-nanomolar levels while retaining druglike properties. The results illustrate that effective use of free energy perturbation can enable a drug discovery campaign to progress rapidly from hit to lead, facilitating proof-of-concept studies that enable target validation.

Identifiants

pubmed: 37060320
doi: 10.1021/acs.jcim.2c01577
doi:

Substances chimiques

Adenylyl Cyclases EC 4.6.1.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2828-2841

Auteurs

Shan Sun (S)

Tri-Institutional Therapeutics Discovery Institute, New York, New York 10021, United States.

Makoto Fushimi (M)

Tri-Institutional Therapeutics Discovery Institute, New York, New York 10021, United States.

Thomas Rossetti (T)

Department of Pharmacology, Weill Cornell Medicine, New York City, New York 10056, United States.

Navpreet Kaur (N)

Department of Pharmacology, Weill Cornell Medicine, New York City, New York 10056, United States.

Jacob Ferreira (J)

Department of Pharmacology, Weill Cornell Medicine, New York City, New York 10056, United States.

Michael Miller (M)

Tri-Institutional Therapeutics Discovery Institute, New York, New York 10021, United States.

Jonathan Quast (J)

Department of Biochemistry, University of Bayreuth, Bayreuth 95440, Germany.

Joop van den Heuvel (J)

Helmholtz-Zentrum für Infektionsforschung, Braunschweig 38124, Germany.

Clemens Steegborn (C)

Department of Biochemistry, University of Bayreuth, Bayreuth 95440, Germany.

Lonny R Levin (LR)

Department of Pharmacology, Weill Cornell Medicine, New York City, New York 10056, United States.

Jochen Buck (J)

Department of Pharmacology, Weill Cornell Medicine, New York City, New York 10056, United States.

Robert W Myers (RW)

Tri-Institutional Therapeutics Discovery Institute, New York, New York 10021, United States.

Stacia Kargman (S)

Tri-Institutional Therapeutics Discovery Institute, New York, New York 10021, United States.

Nigel Liverton (N)

Tri-Institutional Therapeutics Discovery Institute, New York, New York 10021, United States.

Peter T Meinke (PT)

Tri-Institutional Therapeutics Discovery Institute, New York, New York 10021, United States.
Department of Pharmacology, Weill Cornell Medicine, New York City, New York 10056, United States.

David J Huggins (DJ)

Tri-Institutional Therapeutics Discovery Institute, New York, New York 10021, United States.
Department of Physiology and Biophysics, Weill Cornell Medical College of Cornell University, New York, New York 10065, United States.

Articles similaires

Humans Chondrocytes Osteoarthritis Matrix Metalloproteinase 13 Drug Discovery
Receptor, Cannabinoid, CB1 Ligands Molecular Dynamics Simulation Protein Binding Thermodynamics
Humans Acute Kidney Injury Female Male Retrospective Studies
Anthraquinones Kinetics Water Purification Adsorption Thermodynamics

Classifications MeSH